WELLINGTON MANAGEMENT GROUP LLP

Position in ELVN — Enliven Therapeutics, Inc.

CIK 902219 Boston, MA

Position in ELVN

as of Jun 30, 2026 · filed Aug 14, 2026 Compact

Position Value

$6,757,004

+$872,066 QoQ

Shares Held

133,143

-11.3% QoQ

Ownership

0.182%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

#70

of 210 holders

Holding Since

Jun 2024

9 quarters on record

Voting authority Sole 0% Shared 79% None 21%

Healthcare · as of Jun 30, 2026

WELLINGTON MANAGEMENT GROUP LLP holds $14,994,233,945 across 206 Biotechnology names. ELVN ranks #83 (0.0% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	3,247,658	$1,613,209,155
2	ARGX	Argenx SE	930,548	$863,334,513
3	REGN	Regeneron Pharmaceuticals, Inc.	1,270,087	$791,950,042
4	RVMD	Revolution Medicines, Inc.	3,843,415	$719,794,757
5	ALNY	Alnylam Pharmaceuticals, Inc.	2,110,407	$635,295,816
6	IONS	Ionis Pharmaceuticals Inc	7,651,415	$606,680,693
7	CYTK	Cytokinetics Inc	6,931,770	$590,517,483
8	MDGL	Madrigal Pharmaceuticals, Inc.	825,714	$443,367,129

9 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$6,757,004	133,143	-11.3%	Shares	Defined	2026-08-14
2026-03-31	$5,884,938	150,126	+15.6%	Shares	Defined	2026-05-15
2025-12-31	$2,000,089	129,876	+19.6%	Shares	Defined	2026-02-17
2025-09-30	$2,222,222	108,560	+15.5%	Shares	Defined	2025-11-14
2025-06-30	$1,885,879	94,012	+11.0%	Shares	Defined	2025-08-14
2025-03-31	$1,666,895	84,700	+4.7%	Shares	Defined	2025-05-13
2024-12-31	$1,820,610	80,916	+15.3%	Shares	Defined	2025-02-12
2024-09-30	$1,792,141	70,170	+107.0%	Shares	Defined	2024-11-14
2024-06-30	$792,312	33,903	—	Shares	Defined	2024-08-14
No filing history on record for this holder in this stock.